Eli Lilly and Company (LLY)
NYSE • Healthcare
February 17, 2026 at 21:00 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Eli Lilly and Company is a pharmaceutical manufacturer that discovers, develops, and supplies medicines for conditions managed over long periods and in specialized care. The model connects science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use in clinics and hospitals. The company’s priority is continuity — steady supply, clear labeling, and guidance that helps clinicians match therapy to patients. Access programs and country teams adapt to local frameworks while holding to shared safety standards. Digital tools and field support aim to simplify onboarding and monitoring without adding burden to care teams. Within the healthcare sector, Lilly’s role is to make new options feel dependable in daily practice, while continuing to invest in pipelines that can address unmet medical need.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Eli Lilly and Company's Technical Indicators Summary
LLY is currently exhibiting a neutral technical profile as momentum indicators show mixed signals; the RSI and MACD levels suggest a hold, while the Commodity Channel Index and momentum readings lean bearish. The price remains below its short- and medium-term moving averages, all signaling sell, yet it stays well above the long-term averages, which continue to indicate a buying trend. Trend strength is moderate, with the ADX near 24, reflecting neither strong nor weak directional movement. Volatility is steady, supported by an average true range around 3%, while on-balance volume points to some selling pressure. Overall, these factors combine to portray a market balance without clear directional conviction. The technical takeaway is a cautious, neutral stance amid conflicting momentum and trend signals.
| Indicator | Value |
|---|---|
RSI (14) | 46.00 |
Stochastic %K (14, 3, 3) | 25.92 |
CCI (20) | -207.65 |
WPR (14) | -78.72 |
Momentum (10) | -41.96 |
MFI | 29.34 |
MACD Level (12, 26) | 7.19 |
Bollinger Bands | $1035.71 - $1105.28 |
ATR (14) | $31.93 (3.07%) |
ADX (14) | 23.82 |
OBV | 148,788,300 |
Simple Moving Averages | $839.70 - $1070.50(5 indicators) |
Exponential Moving Averages | $891.13 - $1061.89(5 indicators) |
Get premium market insights delivered directly to your inbox.
By the bell, LLY was still trading below yesterday, reflecting a -0.342% opening gap down and a close near 1036.44. The session wrapped with neutral sector performance (-0.16%), offering little macro push or pull. LLY declines amid mixed healthcare headlines and limited stock-specific news today.
Price Change
from $1040 close
-$3.56
Trading Volume
Below avg (4.4M)
2.1M
vs S&P 500 Today
Strong Underperformance
-3.71%
52-Week Position
Upper range
80.9%
Updated: February 17, 2026 at 21:02 UTC
Mixed Global Markets and Key Corporate Moves
February 11, 2026
Analysts Shift on Key Blue-Chip and Growth Names
February 8, 2026
Maersk Cuts Jobs as Freight Rates Slide Further
February 5, 2026
Hims jolts weight‑loss drug market with $49 Wegovy pill
February 5, 2026